CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Cell And Gene Therapy
  • Top Cell and Gene Therapy Companies in APAC

Cell And Gene Therapy 2025

Top 10 Cell and Gene Therapy Companies in APAC - 2025

Top 10 Cell and Gene Therapy Companies in APAC - 2025

The clinical testing landscape in Japan is undergoing a quiet revolution, fueled by the region’s growing leadership in cell and gene therapy. As researchers push forward with hundreds of trials—many now in late-phase development—the country’s regulatory bodies are clearing new paths with designations like “Fast Track” for regenerative treatments. Decentralized and virtual models are opening doors to more diverse patient participation, while AI-driven analytics and real-time monitoring are tightening quality control in cell and gene therapy (CGT) manufacturing.

Behind the scenes, another transformation is unfolding—this time in how pharmaceutical information is communicated. Today’s translation workflows blend advanced neural machine translation tools with expert human oversight to ensure medical content isn’t just accurate but culturally and contextually precise. As life sciences companies look to scale innovations beyond borders, these language services are proving essential in bridging scientific ambition with global execution.

Driven by these trends, the life sciences market is projected to grow at a CAGR of approximately 11.75 percent from 2024 to 2032.

In this edition of Life Sciences Review APAC, we provide insights into recent developments in the life science market and how companies offer services aligned with the latest trends.

The magazine features a thought leadership article by Kazuto Yamada, Senior Director and Head of Clinical Development Planning and Supervising Five R&D Functions at Otsuka Pharmaceutical, highlighting how new technologies like digital biomarkers make clinical trials more patient-focused and efficient. It also features an article from Raymond R. Tjandrawinata, Director of Business Development and Scientific Affairs at Dexa Medica, who sheds light on the urgent need for better quality control in pharmaceuticals.

The edition also features stories of life science companies delivering solutions that play a crucial role in driving innovation. One such company is MILS International, which specializes in advanced metabolic diagnostics using precision metabolomics and medical mass spectrometry.

In this edition featuring Top Clinical Testing Services in Japan 2025, Top Cell and Gene Therapy Company in APAC 2025 and Top Pharmaceutical Translation Services in APAC 2025, we hope you find the right partner to meet your organization's needs.

Top 10 Cell and Gene Therapy Companies in APAC - 2025

Nominate a Company

Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.

* 

captcha
Can't read the image? click here to refresh

Thank You!

checkmark

We are glad to receive your nomination. Our editorial team and evaluation panel will review your submission. Thank you for taking the time to highlight an organization driving impactful change in Lifescience Review.

Data not inserted

    Top Cell and Gene Therapy Companies in APAC

    ★Featured Companies
    M Regenerative Clinic
    M Regenerative Clinic
    Read full profile →
    M Regenerative (MR) Clinic, based in Tokyo, redefines regenerative medicine by merging cutting-edge science with personalized care. The clinic ensures optimal treatment outcomes with an on-site lab, enabling seamless, advanced therapies like stem cells and exosomes. Rooted in holistic principles, it combines innovation and empathy to deliver transformative, patient-centered care worldwide. ... read full profile
    AnGes
    AnGes
    AnGes develops gene-based therapies for unmet medical needs. Its flagship product, Collategene® , is a plasmid DNA drug for angiogenesis. The company’s pipeline includes NF-κB decoy oligonucleotide for chronic pain, DNA vaccines for various conditions, and genome editing technologies, advancing biotechnology to deliver innovative and effective medical solutions.
    Biosyngen
    Biosyngen
    Biosyngen develops cutting-edge immunotherapies for cancer, focusing on CAR-T, TCR-T, and TIL technologies. Its pipeline includes BRG01 for nasopharyngeal cancer, BRL03 for solid tumors, and BST02, a TIL therapy for liver cancer. With GMP facilities in Singapore and China, Biosyngen advances oncology treatments to address critical unmet needs.
    Cartherics
    Cartherics
    Cartherics is a biotechnology company developing innovative, off-the-shelf immunotherapy treatments for solid cancers. By combining gene editing and chimeric antigen receptor (CAR) technology, they create precisely defined cell therapies. Their focus includes developing CAR-NK cells from induced pluripotent stem cells (iPSCs) to enhance accessibility and efficacy in cancer treatment.
    Eutilex
    Eutilex
    Eutilex specializes in immunotherapies for cancer and autoimmune diseases, leveraging proprietary technologies to develop anti-tumor T-cell therapies and antibody therapeutics. Its pipeline includes T Cell Therapy (4-1BB CTL), CAR-T, and antibody treatments. The company advances innovative immune-based solutions to address critical unmet medical needs in oncology and immunology.
    Immunotech Biopharm
    Immunotech Biopharm
    Immunotech Biopharm develops T-cell immunotherapies for cancer, including EAL® , a multitarget therapy for tumor recurrence. Its pipeline features CAR-T and TCR-T therapies, aiming to improve patient survival. Through advanced research and innovation, the company addresses critical unmet needs in oncology, enhancing the effectiveness of immune-based cancer treatments.
    Medinet Co
    Medinet Co
    Medinet Co provides regenerative medicine and cell therapy solutions as a CDMO, specializing in immunocell therapy with comprehensive expertise, facilities, and materials. It operates the Shinagawa Cell Processing Facility in compliance with global regulations. With extensive experience in autologous cell processing, Medinet Co supports regenerative medicine from preclinical research to commercial launch for medical institutions.
    NKMAX
    NKMAX
    NKMAX specializes in immunotherapies and diagnostic solutions centered on Natural Killer (NK) cells. The company offers the NK Vue® Kit, an NK cell activity test, and is developing SuperNK® , an enhanced NK cell-based immunotherapy. It also provides health supplements, recombinant proteins, monoclonal antibodies, and pet health products like NK PUPPY.
    Nuevocor
    Nuevocor
    Nuevocor develops gene therapies for genetic cardiomyopathies using its PrOSIA™ mechanobiology platform. Its lead candidate, NVC-001, targets lamin-related dilated cardiomyopathy (LMNA DCM) to restore cardiac function. The company advances innovative treatments addressing biomechanical defects, supported by significant funding to drive its gene therapy programs forward.
    Rznomics
    Rznomics
    Rznomics develops RNA-based gene therapies using its trans-splicing ribozyme platform. Its lead candidate, RZ-001, targets hepatocellular carcinoma and glioblastoma. Currently in Phase 1/2 trials, the therapy aims to provide innovative treatment options for cancers and other intractable diseases, supported by regulatory designations to accelerate clinical development.
Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://cell-and-gene-therapy-apac.lifesciencesreview.com/vendors/cell-and-gene-therapy-companies-in-apac.html